Patent
Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
1. A composition comprising:
a leukocidin A (LukA) polypeptide analog comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of amino acid residues 28-341 SEQ ID NO: 10, and does not comprise the amino acid sequence of amino acid residues 342-351 of SEQ ID NO: 10.
2. The composition of claim 1 , wherein the LukA polypeptide analog comprises a deletion of amino acid residues 342-351 of SEQ ID NO: 10.
3. The composition of claim 1 , wherein the LukA polypeptide analog comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence of amino acid residues 28-341 of SEQ ID NO: 10.
4. The composition of claim 1 , wherein the LukA polypeptide analog comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence of amino acid residues 28-341 of SEQ ID NO: 10.
5. The composition of claim 1 further comprising:
a pharmaceutically acceptable carrier.
6. The composition of claim 1 further comprising:
an adjuvant.